Voyager Therapeutics (VYGR) Competitors $3.20 0.00 (0.00%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. STOK, SION, IOVA, CDXC, GHRS, EOLS, XNCR, KALV, AUTL, and SANAShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Stoke Therapeutics (STOK), Sionna Therapeutics (SION), Iovance Biotherapeutics (IOVA), ChromaDex (CDXC), GH Research (GHRS), Evolus (EOLS), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Autolus Therapeutics (AUTL), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Stoke Therapeutics Sionna Therapeutics Iovance Biotherapeutics ChromaDex GH Research Evolus Xencor KalVista Pharmaceuticals Autolus Therapeutics Sana Biotechnology Voyager Therapeutics (NASDAQ:VYGR) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Do insiders and institutionals hold more shares of VYGR or STOK? 48.0% of Voyager Therapeutics shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is VYGR or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Voyager Therapeutics' net margin of -126.49%. Stoke Therapeutics' return on equity of 19.08% beat Voyager Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-126.49% -27.36% -21.06% Stoke Therapeutics 26.33%19.08%15.72% Does the media prefer VYGR or STOK? In the previous week, Stoke Therapeutics had 12 more articles in the media than Voyager Therapeutics. MarketBeat recorded 12 mentions for Stoke Therapeutics and 0 mentions for Voyager Therapeutics. Stoke Therapeutics' average media sentiment score of 0.18 beat Voyager Therapeutics' score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Voyager Therapeutics Neutral Stoke Therapeutics Neutral Which has more risk and volatility, VYGR or STOK? Voyager Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Do analysts rate VYGR or STOK? Voyager Therapeutics presently has a consensus price target of $13.39, suggesting a potential upside of 318.44%. Stoke Therapeutics has a consensus price target of $23.20, suggesting a potential upside of 102.00%. Given Voyager Therapeutics' higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has higher valuation and earnings, VYGR or STOK? Voyager Therapeutics has higher revenue and earnings than Stoke Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$80M2.21-$65M-$1.46-2.19Stoke Therapeutics$36.56M17.15-$88.98M$0.7914.54 SummaryStoke Therapeutics beats Voyager Therapeutics on 12 of the 17 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.09M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-2.1921.5027.4220.07Price / Sales2.21282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book0.587.518.015.70Net Income-$65M-$55.05M$3.16B$248.47M7 Day Performance7.74%3.05%2.08%2.92%1 Month Performance-2.44%5.80%4.38%5.77%1 Year Performance-58.60%6.15%35.81%21.39% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics3.9722 of 5 stars$3.20flat$13.39+318.4%-57.8%$177.09M$80M-2.19100STOKStoke Therapeutics4.0381 of 5 stars$11.59+0.1%$23.20+100.2%-10.0%$632.78M$190.91M14.67100Analyst ForecastSIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$622.15MN/A0.0035News CoveragePositive NewsInsider TradeIOVAIovance Biotherapeutics4.7038 of 5 stars$1.85-6.6%$12.22+560.7%-77.4%$617.77M$164.07M-1.49500Trending NewsCDXCChromaDex3.2054 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120GHRSGH Research1.9513 of 5 stars$11.68-5.1%$32.00+174.0%+26.2%$607.71MN/A-14.7810EOLSEvolus4.0912 of 5 stars$9.38+1.1%$23.75+153.2%-13.6%$604.82M$266.27M-10.54170Positive NewsXNCRXencor4.0488 of 5 stars$8.41-1.5%$28.00+232.9%-54.5%$598.54M$110.49M-2.75280KALVKalVista Pharmaceuticals4.2883 of 5 stars$11.93-1.8%$24.83+108.2%+2.3%$593.16MN/A-3.21100Upcoming EarningsAUTLAutolus Therapeutics2.725 of 5 stars$2.21+7.8%$9.32+321.7%-30.5%$588.17M$9.01M-2.51330Positive NewsSANASana Biotechnology2.5755 of 5 stars$2.60-0.4%$10.80+315.4%-45.4%$586.25MN/A-2.95380Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies Stoke Therapeutics Alternatives Sionna Therapeutics Alternatives Iovance Biotherapeutics Alternatives ChromaDex Alternatives GH Research Alternatives Evolus Alternatives Xencor Alternatives KalVista Pharmaceuticals Alternatives Autolus Therapeutics Alternatives Sana Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts